NICE seeks more RoActemra data

The U.K.'s NICE issued a third preliminary appraisal for RoActemra tocilizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat moderate to severe active rheumatoid arthritis, recommending against the mAb against IL-6 in three settings while seeking more information on its use in two others. The agency recommended against RoActemra as monotherapy and in two subsets of patients: those who responded inadequately to one or more previous DMARDs before, or as an alternative to, treatment with TNF alpha inhibitors; and those who responded inadequately to one or more previous TNF inhibitors before, or as an alternative to, treatment with Roche's MabThera rituximab. ...